Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Science versus policy

This article was originally published in The Gray Sheet

Executive Summary

Bipartisan panel issues recommendations to federal agencies Aug. 5 to more clearly distinguish scientific questions from policy disputes in proposed regulations. The Science for Policy Project report also urges more stringent standards against relying on experts with potential conflicts of interest for advisory committees and overall greater transparency in committee selection. The report suggests that a single disclosure form (with some flexibility for special requests) should be developed for all federal advisory panels, drawing off of the current forms for FDA and the Environmental Protection Agency. The panel, supported by the Bipartisan Policy Center, was chaired by former New York Republican Congressman Sherwood Boehlert and former FDA Commissioner and Science magazine editor Donald Kennedy
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT027801

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel